Abstracts Archive - Page 329 of 2607 - ACR Meeting Abstracts

Abstract Number: 0253 • ACR Convergence 2024
Outcomes of Respiratory Syncytial Virus Infection in Patients with Systemic Autoimmune Rheumatic Diseases
Justine Enns¹, Shruthi Srivatsan¹, Bohang Jiang¹, Miao Lin¹, Emily Kowalski², Naomi Patel¹, Xiaosong Wang³, Zachary Williams¹, Grace Qian³, Jennifer Hanberg¹, Colebrook Johnson¹, Madison Negron¹, Katarina Bade², Alene Saavedra², Kevin Mueller², Kathleen Vanni³, Jeffrey Sparks⁴ and Zachary Wallace⁵, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women’s Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ⁵Massachusetts General Hospital, Newton, MA
Background/Purpose: Respiratory Syncytial Virus (RSV) can cause a severe respiratory illness, especially in older adults and those with significant comorbidities. In June 2023 the US…
Abstract Number: 0374 • ACR Convergence 2024
How Do Patient Decision Aids Enable Purposeful Shared Decision-Making in Rheumatology? An Integrative Review
Ibiyemi Oke¹, Ruoning Ni¹ and Bharat Kumar², ¹UNVERSITY OF IOWA HOSPITALS AND CLINICS, Iowa City, IA, ²University of Iowa Hospitals and Clinics, Iowa City, IA
Background/Purpose: Shared decision-making (SDM) is a process in which patients and clinicians work together to make health care decisions. Purposeful SDM (PSDM) is a problem-based…
Abstract Number: 0327 • ACR Convergence 2024
Clinical and Immunological Risk Factors Associated with Fybromialgia in Patients with Idiopathic Inflammatory Myopathies
Samuel Govea-Peláez¹, Beatriz Alcalá-Carmona², Jennifer Balderas Miranda³, Yatzil Reyna-Juárez², María José Ostos-prado², Nancy R Mejía-Domínguez², Guillermo Juarez-Vega⁴, Jiram Torres Ruiz⁵ and Diana Gomez-martin⁶, ¹INCMNSZ, Mexico City, Mexico, ²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, ³Universidad Nacional Autónoma de México, Ciudad de México, Mexico, ⁴Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, ⁵INCMNSZ, Mexico, Federal District, Mexico, ⁶INCMNSZ, Mexico City, Federal District, Mexico
Background/Purpose: Patients with idiopathic inflammatory myopathies (IIM) have reported chronic pain despite having normal serum muscular enzymes, physician global assessment (PhGA) and MMT8 scores, thus…
Abstract Number: 0264 • ACR Convergence 2024
Clinical Value of Metagenomic Next-generation Sequencing in Patients with Connective Tissue Disease Co-infections: A Single-center Study from Southern Hospital in China
Yuan-Yuan Xiao¹, Ai-Ling Lu¹, Han-You Mo², Zhen-Dong He², Jia-Le Wen² and Xuan Yin¹, ¹Guilin Medical University, Guilin, China (People's Republic), ²The First Affiliated Hospital of Guangxi Medical University, Nanning, China (People's Republic)
Background/Purpose: Few studies have been reported on the use of metagenomic next-generation sequencing (mNGS) in patients with connective tissue disease (CTD) co-infections, and more relatively large-scale data…
Abstract Number: 0403 • ACR Convergence 2024
Comparing Domains Reported by Patients and Other Collaborators in CNO and SAPHO: A Qualitative Study and Scoping Review Using the OMERACT Process
Melissa Oliver¹, susan Thornhill², Beverley Shea³, Jonathan Akikusa², Christian Hedrich⁴, Philip Mease⁵ and Yongdong (Dan) Zhao⁶, and OMERACT CNO & SAPHO Working Group, ¹Indiana University, Indianapolis, IN, ²Royal Children's Hospital, Parkville, Victoria, Australia, ³Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁴University of Liverpool, Liverpool, United Kingdom, ⁵Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ⁶University of Washington, Redmond, WA
Background/Purpose: Disease outcome measures for chronic nonbacterial osteomyelitis (CNO) & Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis (SAPHO) have been proposed and reported but have lacked…
Abstract Number: 0393 • ACR Convergence 2024
Effectiveness of Secukinumab in TMJ Symptoms in Children with JPsA and ERA: A Secondary Data Analysis of JUNIPERA
Marianne Kerski¹, Smriti Mohan¹, Cynthia Vizcaya², Reema Sutariya³, Weibin Bao³ and Matthew Stoll⁴, ¹University of Michigan, Ann Arbor, MI, ²Novartis Pharmaceutical Corporation, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Early recognition and treatment of temporomandibular joint (TMJ) arthritis in children with juvenile idiopathic arthritis (JIA) is of high importance given its impact on…
Abstract Number: 0400 • ACR Convergence 2024
Osteoclastogenesis from Peripheral Blood Mononuclear Cells in Children with Chronic Nonbacterial Osteomyelitis Are Similar to Those from Healthy Children
Jacqueline Bui¹, Jacob Curry², Jessica Kent³, Payton Danosky⁴, Kellen Sanders⁴, Sriya Paluvayi⁴, Wendy Garcia⁴, Alejandra Ruppe⁴, Megan Cheung⁴, Anna Saack⁴, Xinrui Bao⁴, Audrey Luey⁴, Michelle Kim⁴, Emily McDaniel⁴, Amanda Chiu⁴, Sophia Ahn⁵, Ji-Won Park⁴, Sudheshna Thirunahari⁴, Cammie Wei⁴, Liau Adriel⁵, Sophia Pham⁴, Sadie Van Den Bogaerde⁴, Joshua Scheck⁴, Ian Muse⁶, Ava Klein⁵, Xing Wang⁷, James Cassat⁸ and Yongdong Zhao⁶, ¹Seattle Children’s Research Institute, University of Washington, Bellevue, WA, ²Seattle Children’s Research Institute, Vanderbilt University Medical Center, Seattle, WA, ³Seattle Children’s Research Institute, Medical College of Wisconsin, Seattle, WA, ⁴Seattle Children’s Research Institute, University of Washington, Seattle, WA, ⁵Seattle Children’s Research Institute, University of Washington, Seattle, ⁶Seattle Children's Research institute, Seattle, WA, ⁷Biostatistics Epidemiology and Analytics in Research, Seattle Children’s Research Institute, Seattle, WA, ⁸Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease in which osteoclastogenesis may play a critical role. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) was shown…
Abstract Number: 0412 • ACR Convergence 2024
Impact of Approval of Biologic DMARDs on JIA Outcomes in a Single Center
Anna Sutton¹, Erin Balay-Dustrude¹, Beth A Mueller¹ and Susan Shenoi², ¹University of Washington, Seattle, WA, ²Seattle Children's Hospital and Research Center, Mercer Island, WA, WA
Background/Purpose: In clinical trials, biologic disease-modifying antirheumatic drugs (bDMARDs) for juvenile idiopathic arthritis (JIA) have demonstrated good efficacy. However, less is known about the impact…
Abstract Number: 0391 • ACR Convergence 2024
Using Machine Learning to Predict Inactive Disease in Juvenile Idiopathic Arthritis
Mei-Sing Ong¹, Marc Natter², Laura Schanberg³ and Yukiko Kimura⁴, and CARRA Registry Investigators, ¹Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA, ²Boston Children's Hospital, Boston, MA, ³Duke University Medical Center, DURHAM, NC, ⁴Hackensack Meridian School of Medicine, New York, NY
Background/Purpose: Optimizing treatment of JIA continues to be a challenge. Biologic DMARD (bDMARD) therapies have significantly improved outcomes but is costly, may be more difficult…
Abstract Number: 0405 • ACR Convergence 2024
Olokizumab, a Monoclonal Antibody Against IL-6, in Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA): Results of 24 Weeks of the Phase 2 Open-label Clinical Trial
Ekaterina Alexeeva¹, Tatiana Dvoryakovskaya², Elena Zholobova³, Elizaveta Krekhova⁴, Rinat Raupov⁵, Daria Bukhanova⁶, Alina Egorova⁶, Sofia Kuzkina⁶, Mikhail Samsonov⁶, Irina Nikishina⁷ and Mikhail Kostik⁵, ¹National Medical Research Center of Children's Health, Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, ²National Medical Research Center of Children's Health, Moscow, Russia, ³Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, ⁴National Medical Research Centre for Children's Health, Moscow, Russia, ⁵Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ⁶R-Pharm, Moscow, Russia, ⁷V. A. Nasonova Research Institute of Rheumatology, Moscow, Russia
Background/Purpose: Olokizumab (OKZ) is a direct interleukin-6 inhibitor for treatment of rheumatoid arthritis and is being investigated in the open-label Phase 2 trial in adolescents…
Abstract Number: 0358 • ACR Convergence 2024
Residual’ Fatigue and Its Severity in Patients with Rheumatoid Arthritis in Clinical Remission: Prevalence and Associated Factors
Rosa Maria Morlà Novell¹, Beatriz Frade-Sosa², Lola Tobalina Maestre³, Meritxell Sallés Lizarzaburu⁴, Virginia Ruiz-Esquide², Maria López Lasanta⁵, Georgina Salvador Alarcón⁶, Noemí Busquets Pérez⁷, Marta Valls Roc⁸, Enrique Gonzalez Dávila⁹, Jose Alfredo Gomez-Puerta¹⁰ and Raimon Sanmartí Sala¹⁰, and ARCat study Group, ¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Hospital Clinic de Barcelona, Barcelona, Spain, ³Fundació Clinic per la Recerca clínica, Barcelona, Spain, ⁴Althaia Xarxa Assistencial Universitària Manresa, Manresa, Catalonia, Spain, ⁵Hospital Universitari Vall d´Hebron, Rheumatology, Barcelona, Spain, ⁶Hospital Mútua de Terrassa, Terrassa, Spain, ⁷HOSP. GENERAL DE GRANOLLERS, GRANOLLERS, Spain, ⁸Hospital Universitari Josep Trueta, Girona, ⁹Universidad de La Laguna, Santa Cruz de Tenerife, Spain, ¹⁰Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain
Background/Purpose: Fatigue is a frequent and annoying symptom in rheumatoid arthritis (RA) patients that is often not assessed at routine follow-up visits. Residual’ fatigue has…
Abstract Number: 0136 • ACR Convergence 2024
Demographic and Clinical Characteristics of Patients with SLE Across 5 Registries – the LupusNet Federated Data Network
Federico Zazzetti¹, Urbano Sbarigia², William Giovanini³, Claire Blacketer⁴, Michel van Speybroeck⁵, Teresa A. Simon⁶, Guo Li³, Chetan S. Karyekar⁴, Reyhan Sonmez⁷, Manuel Ugarte-Gil⁸, RV, Gamboa-Cardenas⁹, Victor Pimentel-Quiroz¹⁰, Guillermo Pons-Estel¹¹, Bernardo Pons-Estel¹², Rosana Quintana¹³, Veronica Saurit¹⁴, ODIRLEI MONTICIELO¹⁵, Katiuzka Zuñiga Corrales¹⁶, Jorge Esquivel-Valerio¹⁷, Martin Rebella¹⁸, Cecilia Pisoni¹⁹, Francinne Machado Ribeiro²⁰, Carlos Núñez-Álvarez²¹, Kaleb Michaud²², Patricia Katz²³, Rangi Kandane-Rathnayake²⁴, Eric Morand²⁵, Worawit Louthrenoo²⁶, Yi-Hsing Chen²⁷, Jiacai Cho²⁸, Laniyati Hamijoyo²⁹, Shue Fen Luo³⁰, Yeong-Jian Jan Wu³⁰, Sandra Navarra³¹, Sargunan Sockalingam³², Masayoshi Harigai³³, Zhuoli Zhang³⁴, BMDB Basnayake³⁵, Madelynn Chan³⁶, Tsutomu Takeuchi³⁷, Sang-Cheol Bae³⁸, Fiona Goldblatt³⁹, Sean O'Neill⁴⁰, Kristine (Pek Ling) Ng⁴¹, Yih Jia Poh⁴², Nicola Tugnet⁴³, Sunil Kumar⁴⁴, Michael Tee⁴⁵, Yoshiya Tanaka⁴⁶ and Chak Sing. Lau⁴⁷, Alberta Hoi⁴⁸, Mandana Nikpour⁴⁹, Mark Sapsford⁵⁰, Íñigo Rúa-Figueroa⁵⁰, José María Pego-Reigosa⁵¹, María Galindo-Izquierdo⁵², Jaime Calvo-Alén⁵³, Antonio Fernández-Nebro⁵⁴, Raúl Menor Almagro⁵⁵ and Frederic Lavie⁵⁶, ¹Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ²Johnson & Johnson Innovative Medicine, Brussels, Belgium, ³The Janssen Pharmaceutical Companies of Johnson & Johnson, Titusville, NJ, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Pharmaceutica, Beerse, Belgium, ⁶Physicians Research Center, LLC, Toms River, NJ, ⁷EFOR-CVO Life Sciences Consultancy, Basel, Switzerland, ⁸Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas. Universidad Científica del Sur. Lima. Perú Servicio de Reumatología. Hospital Guillermo Almenara Irigoyen-EsSalud, Lima, Peru, ⁹Universidad Científica del Sur, Lima, Lima, Peru, ¹⁰Universidad Científica del Sur/Hospital Nacional Guillermo Almenara Irigoyen, Magdalena del Mar, Peru, ¹¹Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina, ¹²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, ¹³Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ¹⁴hospital privado universitario de cordoba, Córdoba, Argentina, ¹⁵HOSPITAL DE CLINICAS DE PORTO ALEGRE, PORTO ALEGRE, Rio Grande do Sul, Brazil, ¹⁶Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, ¹⁷Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, ¹⁸Unidad Enfermedades Autoinmunes Sistemicas, Clinica Medica C-Hospital de Clinicas, UDELAR Montevideo, Montevideo, Uruguay, ¹⁹CEMIC, Buenos Aires, Argentina, ²⁰Hospital Universitario Pedro Ernesto, UERJ, Rio De Janeiro, Brazil, Rio de Janeiro, Brazil, ²¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CDMX, Mexico, Mexico, Mexico, ²²University of Nebraska Medical Center, Omaha, NE, ²³University of California San Francisco, San Francisco, CA, ²⁴Monash University, Clayton, Victoria, Australia, ²⁵School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ²⁶Chiang Mai University, Chang Wat Chiang Mai, Thailand, ²⁷Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ²⁸National University Hospital, Kent Ridge, Singapore, ²⁹University of Padjadjaran, Sumedang Regency and Bandung, Indonesia, ³⁰Chang Gung Memorial Hospital, Taoyuan City, Taiwan (Republic of China), ³¹University of Santo Tomas, Manila, Philippines, ³²University of Malaya Medical Centre, Kuala Lumpur, Malaysia, ³³Tokyo Women's Medical University, Tokyo, Japan, ³⁴Peking University First Hospital, Beijing, China, ³⁵Teaching Hospital, Kandy, Sri Lanka, ³⁶Tan Tock Seng Hospital, Singapore, Singapore, ³⁷Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ³⁸Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³⁹Flinders Medical Centre, Adelaide, Australia, ⁴⁰Liverpool Hospital; Royal North Shore Hospital; University of New South Wales and the University of Sydney, Sydney, New South Wales, Australia, ⁴¹Health New Zealand Waitemata, Te Whatu Ora (North Shore Hospital), Auckland, New Zealand, ⁴²SingHealth, Singapore, Singapore, ⁴³Auckland District Health Board, Auckland, New Zealand, ⁴⁴Health New Zealand Counties Manukau, Te Whatu Ora (Middlemore Hospital), Auckland, New Zealand, ⁴⁵University of the Philippines, Manila, Philippines, ⁴⁶Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁴⁷University of Hong Kong, Pok Fu Lam, Hong Kong, ⁴⁸Monash Health, Monash University, Melbourne, AU, Melbourne, Victoria, Australia, ⁴⁹The University of Sydney, Melbourne, Victoria, Australia, ⁵⁰Middlemore Hospital, Auckland, New Zealand, ⁵⁰Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, ⁶Galicia Health Service (SERGAS), Vigo, Spain, ⁵²Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁵³Department of Rheumatology, Hospital Araba, Vitoria, Pais Vasco, Spain, ⁵⁴Department of Rheumatology, Hospital Universitario de Málaga, Málaga, Andalucia, Spain, ⁵⁵Department of Rheumatology, Hospital Jerez de la Frontera, Jerez de la Frontera, Spain, ⁵⁶Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with a broad range of clinical manifestations and a high unmet need across patient populations. Real-world…
Abstract Number: 0394 • ACR Convergence 2024
Unveiling Major Challenges and Unmet Needs in the Therapeutic Approach to Systemic Juvenile Idiopathic Arthritis: The Patient Perspective
Francesco Baldo¹, Luciana Peixoto², Remco Erkens³, Greta Rogani³, Claudia Bracaglia⁴, Dirk Foell⁵, Marco Gattorno⁶, Marija Jelusic⁷, Sebastiaan Vastert³, Rashmi Sinha² and Francesca Minoia⁸, and on behalf of the PReS MAS/sJIA Working Party and the Systemic JIA Foundation, ¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ²Systemic JIA Foundation, Cincinnati, OH, ³University Medical Center Utrecht, Utrecht, Netherlands, ⁴IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁵University Hospital Muenster, Muenster, Germany, ⁶IRCCS Giannina Gaslini, Genoa, Italy, ⁷University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, ⁸Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Milan, Italy
Background/Purpose: Despite continuous improvements in the therapeutic options for children with systemic juvenile idiopathic arthritis (sJIA), access to medications significantly differs among centres and countries.…
Abstract Number: 0272 • ACR Convergence 2024
Calcifications of the Transverse Ligament of the Atlas in Patients Diagnosed with Calciumpyrophosphate Crystal Arthritis – a Retrospective Observational Study
Shay Brikman¹, Noga Shabshin² and Amir Bieber³, ¹Emek Medical Center, Afula, Israel, ²Emek Medical Center, Clalit Health Services, Afula, Israel, ³Emek Medical Center, Clalit Health Services, Raanana, Israel
Background/Purpose: Chondrocalcinosis (CC) is commonly detected on X-ray films of the knee, wrist, and symphysis pubis. Calcium pyrophosphate (CPP) deposition disease is sometimes associated with…
Abstract Number: 0270 • ACR Convergence 2024
Longitudinal Patterns of C-Reactive Protein Values in Calcium Pyrophosphate Deposition (CPPD) Disease
Muneet Gill, Hongshu Guan, Jamie Collins and Sara Tedeschi, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease is a crystalline arthritis affecting older adults. Systemic inflammation occurs during flares of acute calcium pyrophosphate (CPP) crystal arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].